Banxia Xiexin Decoction Ameliorates Ulcerative Colitis via a Flora‐Metabolite‐Inflammation Axis Through Integrated Metabolomic and Microbiome Analysis
Biomedical Chromatography · 2026-01 · 40 (1)
DOI: 10.1002/bmc.70275 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 30.11.2025. Verfasst von Feng Ying und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anus and Intestine Surgery, Yongkang First People's Hospital Affiliated to Hangzhou Medical College, Yongkang, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Colitis, Ulcerative, Gastrointestinal Microbiome, Metabolome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Jinhua Science and Technology Project.
Abstract (Originalsprache)
Banxia Xiexin Decoction (BXD), a classic traditional Chinese medicine formula traditionally used for gastrointestinal disorders, has demonstrated considerable therapeutic potential in ulcerative colitis (UC). Yet, its mechanism of action remains incompletely elucidated. In this study, we applied an integrated strategy incorporating UPLC‐Q‐TOF/MS‐based plasma metabolomics and gut microbiome analysis to explore the anti‐UC effects of BXD. In a DSS‐induced murine model of UC, BXD treatment mitigated colonic inflammation, as evidenced by reduced levels of pro‐inflammatory cytokines (IL‐1β, IL‐6, and TNF‐α), repaired intestinal barrier integrity, and restored metabolic homeostasis via regulation of tryptophan and nitrogen metabolism. Notably, BXD promoted the production of microbially derived tryptophan metabolites, including indole‐3‐propionic acid (IPA) and indole‐3‐carboxaldehyde (IAld). IAld acts as a ligand for the aryl hydrocarbon receptor (AhR), facilitating the differentiation and function of regulatory T cells (Tregs) and thereby helping to suppress excessive inflammation. Gut microbiota analysis further indicated that BXD enriched beneficial genera such as Akkermansia and Bifidobacterium , while reducing the abundance of pro‐inflammatory bacteria belonging to the Lachnospiraceae family. These results demonstrate the role of BXD in modulating the flora‐metabolite‐inflammation axis, providing a scientific rationale for its use in UC and highlighting its multi‐target actions involving anti‐inflammatory effects, metabolic reprogramming, and microbiota restoration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anus and Intestine Surgery, Yongkang First People's Hospital Affiliated to Hangzhou Medical College, Yongkang, China.
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
ORCID-Profile: Xiangwei Xu, Yi Tao
Förderung
- Jinhua Science and Technology Project
Zitieren
APA
Ying, F., Shao, W., Li, L., Cao, X., Xu, X., & Tao, Y. (2026). Banxia Xiexin Decoction Ameliorates Ulcerative Colitis via a Flora‐Metabolite‐Inflammation Axis Through Integrated Metabolomic and Microbiome Analysis. Biomedical Chromatography, 40(1). https://doi.org/10.1002/bmc.70275
Vancouver
Ying F, Shao W, Li L, Cao X, Xu X, Tao Y. Banxia Xiexin Decoction Ameliorates Ulcerative Colitis via a Flora‐Metabolite‐Inflammation Axis Through Integrated Metabolomic and Microbiome Analysis. Biomedical Chromatography. 2026;40(1). doi:10.1002/bmc.70275
BibTeX
@article{Ying2026,
author = {Ying, Feng and Shao, Wentao and Li, Long and Cao, Xinmei and Xu, Xiangwei and Tao, Yi},
title = {Banxia Xiexin Decoction Ameliorates Ulcerative Colitis via a Flora‐Metabolite‐Inflammation Axis Through Integrated Metabolomic and Microbiome Analysis},
journal = {Biomedical Chromatography},
year = {2026},
volume = {40},
number = {1},
doi = {10.1002/bmc.70275}
}
EUVIMED